Verender Badial - Zura Bio Chief Officer
| ZURA Stock | 2.73 0.20 6.83% |
Executive
Verender Badial is Chief Officer of Zura Bio Limited
| Age | 52 |
| Address | 1489 W. Warm Springs Road, Henderson, NV, United States, 89014 |
| Phone | 702-757-6133 |
| Web | https://zurabio.com |
Zura Bio Management Efficiency
The company has return on total asset (ROA) of (0.214) % which means that it has lost $0.214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3685) %, meaning that it created substantial loss on money invested by shareholders. Zura Bio's management efficiency ratios could be used to measure how well Zura Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.57. The current year's Return On Capital Employed is expected to grow to -0.74. At present, Zura Bio's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 105.9 M, whereas Total Assets are forecasted to decline to about 90.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| RPh Young | Seres Therapeutics | 57 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Lee Flowers | HCW Biologics | 78 | |
| JD Esq | Seres Therapeutics | 69 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| David Ege | Seres Therapeutics | 49 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.21 |
Zura Bio Limited Leadership Team
Elected by the shareholders, the Zura Bio's board of directors comprises two types of representatives: Zura Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zura. The board's role is to monitor Zura Bio's management team and ensure that shareholders' interests are well served. Zura Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zura Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Whale, Chief Officer | ||
| David Brady, Head Development | ||
| Kiran MBBS, Chief Development | ||
| Kimberly Davis, Chief Secretary | ||
| Theresa Lowry, Chief Officer | ||
| Verender Badial, Chief Officer | ||
| Michael Howell, Chief Medicine | ||
| Someit MD, Founder Director | ||
| Robert Lisicki, President COO |
Zura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zura Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 178.59 M | ||||
| Shares Outstanding | 63.77 M | ||||
| Shares Owned By Insiders | 31.87 % | ||||
| Shares Owned By Institutions | 53.29 % | ||||
| Number Of Shares Shorted | 1.75 M | ||||
| Price To Book | 1.16 X | ||||
| EBITDA | (60.56 M) | ||||
| Net Income | (60.56 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zura Bio Limited offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zura Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zura Bio Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zura Bio Limited Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zura Bio Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zura Bio. If investors know Zura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zura Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.57 | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Zura Bio Limited is measured differently than its book value, which is the value of Zura that is recorded on the company's balance sheet. Investors also form their own opinion of Zura Bio's value that differs from its market value or its book value, called intrinsic value, which is Zura Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zura Bio's market value can be influenced by many factors that don't directly affect Zura Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zura Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zura Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zura Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.